Lipella Pharmaceuticals Changes Fiscal Year End
Ticker: LIPO · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: fiscal-year-change, financial-reporting, administrative
Related Tickers: LIP
TL;DR
Lipella Pharma (LIP) is changing its fiscal year end to Dec 31st, filing financials on 4/12.
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on April 12, 2024, reporting a change in its fiscal year end to December 31st. This filing also includes financial statements and exhibits, with the earliest event reported occurring on April 11, 2024. The company is incorporated in Delaware and headquartered in Pittsburgh, PA.
Why It Matters
A change in fiscal year end can impact reporting schedules and financial analysis, potentially affecting investor perception and investment decisions.
Risk Assessment
Risk Level: low — This filing primarily concerns administrative changes and financial reporting, with no immediate indication of significant operational or financial distress.
Key Numbers
- 12/31 — Fiscal Year End (Updated from previous year-end to December 31st.)
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- April 12, 2024 (date) — Date of Report
- April 11, 2024 (date) — Earliest Event Reported
- December 31st (date) — New Fiscal Year End
- Pittsburgh, PA (location) — Principal Executive Office
FAQ
What is the new fiscal year end for Lipella Pharmaceuticals Inc.?
The company has changed its fiscal year end to December 31st.
When was this 8-K filing submitted?
The filing was submitted on April 12, 2024.
What is the earliest event date reported in this filing?
The earliest event reported is dated April 11, 2024.
Where is Lipella Pharmaceuticals Inc. headquartered?
The company's principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What type of information is included in this 8-K filing besides the fiscal year change?
The filing also includes financial statements and exhibits.
Filing Stats: 587 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-04-12 16:15:52
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar
Filing Documents
- g084176_8k.htm (8-K) — 32KB
- g084176_ex3-1.htm (EX-3.1) — 6KB
- ex3-1_pg1.jpg (GRAPHIC) — 76KB
- ex3-1_pg2.jpg (GRAPHIC) — 244KB
- ex3-1_pg3.jpg (GRAPHIC) — 38KB
- 0001753926-24-000721.txt ( ) — 706KB
- lipo-20240412.xsd (EX-101.SCH) — 3KB
- lipo-20240412_lab.xml (EX-101.LAB) — 33KB
- lipo-20240412_pre.xml (EX-101.PRE) — 22KB
- g084176_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 12, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer